文献速递瓣膜外科

MitraClip适应证过宽及失败后延迟转外科手术的警示

MitraClip: a word of caution regarding an all too liberal indication and delayed referral to surgery in case of failure.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该回顾性研究分析49例MitraClip植入后行二尖瓣置换术的患者,平均间隔8±12个月。术后30天和1年死亡率分别为26.5%和59.2%。植入后三尖瓣反流和右心功能显著恶化,肺动脉压升高。作者警示应审慎把握MitraClip适应证并加强监测,失败后尽早转外科手术。

要点

  • MitraClip失败后延迟转外科手术与右心功能恶化相关。
  • 49例患者二尖瓣置换术后30天死亡率为26.5%。
  • 应审慎评估MitraClip适应证并密切监测。

核心结论

  • 部分患者不能从MitraClip获益,心脏功能进行性恶化,最终不可避免地在困难条件下行瓣膜置换。
  • 这些患者越早手术越好,部分患者直接手术可能更优,尤其当二尖瓣修复仍可行时。
  • 应审慎考虑MitraClip适应证并在监测中保持警惕。

研究设计与样本

  • 回顾性分析49例接受二尖瓣置换术的患者,平均在MitraClip植入后8±12个月进行手术。
  • 53%的患者植入了2-4个夹子,平均年龄73岁,平均log EuroSCORE为20.79±14.42%。
  • 回顾了MitraClip植入前及心脏手术后10天、6个月和12个月的超声心动图数据,并分析生存、风险特征和术后并发症。

主要发现

  • 30天死亡率为26.5%,1年死亡率为59.2%。
  • MitraClip植入前,42.8%的患者有轻度三尖瓣关闭不全,6.1%有中度三尖瓣关闭不全。
  • 手术前,26.5%有轻度、32.7%有中度、38.8%有重度三尖瓣关闭不全(P < 0.001)。
  • MitraClip植入后,经三尖瓣环平面收缩期位移评估的右心功能显著恶化(P < 0.001)。
  • 在行二尖瓣置换时,有MitraClip的患者肺动脉压显著高于MitraClip植入前(P < 0.001)。

临床怎么用

  • 对拟行MitraClip的患者应严格评估适应证,避免过度放宽。
  • MitraClip术后应密切监测右心功能、三尖瓣反流和肺动脉压。
  • 若MitraClip效果不佳,应尽早转诊外科手术,避免延迟导致心功能进一步恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although indications for the MitraClip are becoming increasingly liberal, the number of patients requiring valve surgery after an insufficient outcome of the procedure is growing. Referral to surgery is, however, frequently delayed. During this time, the patients often deteriorate. We retrospectively analysed patients before MitraClip implantation and after mitral valve surgery. METHODS: A total of 49 patients who received a mitral valve replacement (average 8 ± 12 months after MitraClip implantation) were assessed. Of these, 53% had 2-4 clips inserted. The mean age was 73 years, and the mean log EuroSCORE was 20.79 ± 14.42%. Echocardiographic data obtained prior to MitraClip implantation and preoperatively, 10 days and 6 and 12 months after cardiac surgery were reviewed. Survival analysis, risk profile and postoperative complications were analysed. RESULTS: The 30-day and 1-year mortality was 26.5% and 59.2%, respectively. Prior to MitraClip implantation, 42.8% of patients had mild tricuspid insufficiency and 6.1% had moderate tricuspid insufficiency. Prior to surgery, 26.5% showed mild, 32.7% moderate and 38.8% severe tricuspid insufficiency (P < 0.001). Furthermore, right heart function assessed by tricuspid annular plane systolic excursion deteriorated significantly after Implantation of the MitraClip (P < 0.001). In patients with a MitraClip, the pulmonary artery pressure was significantly higher at the time of mitral replacement than it was before the MitraClip was implanted (P < 0.001). CONCLUSIONS: A subgroup of patients does not benefit from a MitraClip and shows progressive deterioration in cardiac function, making valve replacement under difficult circumstances inevitable. The earlier these patients are operated on, the better it is. It can be assumed that some patients would be better off with primary surgery, especially if mitral reconstruction is then still feasible. Therefore, the indications for MitraClip implantation should be carefully considered and caution should be exercised during monitoring.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Ostovar R, Erb M, Schroeter F, et al. MitraClip: a word of caution regarding an all too liberal indication and delayed referral to surgery in case of failure. Eur J Cardiothorac Surg. 2021. PMID: 33367523. doi:10.1093/ejcts/ezaa444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。